Skip to main content

Table 3 Association between atopy and incidence of respiratory symptoms stratified by the treatment group and gender

From: Atopy is a risk factor for respiratory symptoms in COPD patients: results from the EUROSCOP study

Respiratory symptom

Total population

Males

Females

 

OR (95% CI) of atopy

OR (95% CI) of atopy

OR (95% CI) of atopy

 

Placebo

Budesonide

Placebo

Budesonide

Placebo

Budesonide

Wheezing at any time

1.15 (0.71–1.87)

0.79 (0.45–1.43)

1.24 (0.74–2.08)

0.92 (0.48–1.75)

0.64 (0.15–2.78)

0.43 (0.10–1.85)

Cough day/night or a.m.

1.79 (1.03–3.08) *

0.83 (0.42–1.62)

1.69 (0.93–3.08)#

0.84 (0.38–1.84)

2.52 (0.64–9.86)

0.60 (0.17–2.08)

Phlegm day/night or a.m.

1.50 (0.84–2.69)

0.91 (0.54–1.53)

1.55 (0.82–2.93)

0.85 (0.46–1.59)

1.30 (0.36–4.67)

0.92 (0.38–2.27)

Trouble with breathing

1.12 (0.66–1.89)

0.68 (0.37–1.24)

1.09 (0.59–1.99)

0.79 (0.42–1.51)

1.23 (0.44–3.44)

0.22 (0.4–1.13)#

Woken with chest tightness

1.33 (0.74–2.38)

1.07 (0.57–1.99)

1.35 (0.69–2.65)

1.08 (0.55–2.12)

1.08 (0.27–4.34)

1.11 (0.23–5.39)

Attack of dyspnea after activity

0.98 (0.59–1.62)

1.49 (0.88–2.51)

0.76 (0.43–1.33)

1.55 (0.88–2.73)$

2.79 (0.94–8.31)#

0.89 (0.22–3.62)

  1. *OR is significant at p < 0.05. Each model was adjusted for sex, age, BMI, pack years of smoking, number of cigarettes and FEV1 % pred.
  2. #Trend (0.05 < p. value < 0.1).
  3. $Interaction between Phadiatop and treatment group has a p.value < 0.05.